Trial Profile

A Phase 1, Open Label, Safety, Tolerability, and Pharmacokinetic Study of Tucatinib (ONT-380) in Healthy Japanese and Caucasian Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 02 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tucatinib (Primary)
Indications Breast cancer; Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer; Gastrointestinal cancer; Non-small cell lung cancer; Solid tumours
Focus Pharmacokinetics
Sponsors Seagen; Seattle Genetics

Most Recent Events

17 Sep 2021 Results presented at the 2021 American College of Clinical Pharmacology Annual Meeting
03 Sep 2019 Status changed from recruiting to completed.
16 May 2019 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com